-
Mashup Score: 2
Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart disease1 Label update reinforces robust safety and effectiveness data for LeqvioEAST…
Categories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study of a CDK4/6 inhibitor demonstrating consistent benefit in a broad population of patients with stage II and III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with no nodal…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Novartis announces FDA approval of BEOVU® for the treatment of diabetic macular edema | Novartis United States of America - 2 year(s) ago
Published on Jun 01, 2022
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 1Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™ | Novartis United States of America - 3 year(s) ago
Published on Mar 17, 2021
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 7Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™ | Novartis United States of America - 3 year(s) ago
Published on Mar 17, 2021
Categories: Latest Headlines, OphthalmologyTweet
On July 7 Novartis received FDA approval for a label update allowing use of Leqvio ® (inclisiran) in certain patients at high risk of CVD. Read full info here: https://t.co/IvEg9LGjzV